Application of electroporation in DNA vaccination protocols

Current Gene Therapy

Volumn 10, Issue 4, 2010, Pages 281-286

  Chiarella, Pieranna ^a,b   Fazio, Vito M ^a   Signori, Emanuela ^a,b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b CNR   (Italy)

Author keywords

Cancer vaccines; DNA vaccines; Electroporation; Gene therapy

Indexed keywords

CANCER VACCINE; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5B; PLASMID DNA; PROSTATE SPECIFIC ANTIGEN; PROSTATE STEM CELL ANTIGEN; PROTEIN E6; PROTEIN E7;

ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CLINICAL TRIAL; DNA IMMUNIZATION; DNA TRANSFER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPORATION; GENE THERAPY; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; NONHUMAN; PROSTATE CANCER;

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; COMMUNICABLE DISEASES; DNA; ELECTROPORATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MALE; MICE; NEOPLASMS; PLASMIDS; VACCINATION; VACCINES, DNA;

ANIMALIA;

EID: 77958026029     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652310791823506     Document Type: Article

References (61)

1. Wiendl H, Hohlfeld R, Kieseier BC. Immunobiology of muscle:advances in understanding an immunological microenvironment. Trends Immunol 2005; 26: 373-80.
2. Stan AC, Casares S, Brumeanu TD, Klinman DM, Bona CA. Cp Gmotifs of DNA vaccines induce the expression of chemokines andMHC class II molecules on myocytes. Eur J Immunol 2001; 31: 301-10.
3. Shirota H, Petrenko L, Hong C, Klinman DM. Potential of transfectedmuscle cells to contribute to DNA vaccine immunogenicity. J Immunol 2007; 179: 329-36.
4. + T cells. J Immunol 2006; 177: 6626-6633.
5. Rice J, Elliott T, Buchan S, Stevenson FK. DNA fusion vaccinedesigned to induce cytotoxic T cell responses against defined peptidemotifs: implications for cancer vaccines. J Immunol 2001; 167: 1558-65.
6. Mir LM, Bureau MF, Gehl J, et al. High-efficiency gene transferinto skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999; 96(8): 4262-7.
7. Favard C, Dean DS, Rols MP. Electrotransfer as a non viral methodof gene delivery. Curr Gene Ther 2007; 7: 67-77.
8. André FM, Gehl J, Sersa G, et al. Efficiency of high-and lowvoltagepulse combinations for gene electrotransfer in muscle,liver, tumor, and skin. Hum Gene Ther 2008; 19: 1261-71.
9. Peng B, Zhao Y, Xu L, Xu Y. Electric pulses applied prior to intramuscularDNA vaccination greatly improve the vaccine immunogenicity. Vaccine 2007; 25: 2064-73.
10. Scheerlinck JP, Karlis J, Tjelle TE, et al. In vivo electroporationimproves immune responses to DNA vaccination in sheep. Vaccine 2004; 22: 1820-5.
11. Babiuk S, Baca-Estrada ME, Foldvari M, et al. Electroporationimproves the efficacy of DNA vaccines in large animals. Vaccine 2002; 20: 3399-408.
12. Tollefsen S, Tjelle TE, Schneide J, et al. Improved cellular andhumoural immune responses against Mycobacterium tubercolosisantigens after intramuscular DNA immunisation combined withmuscle electroporation. Vaccine 2002; 20: 3370-3378.
13. Dupuis M, Denis-Mize K, Woo C, et al. Distribution of DNA vaccinesdetermines their immunogenicity after intramuscular injectionin mice. J Immunol 2000; 165: 2850-8.
14. Widera G, Austin M, Rabussay D, et al. Increased DNA vaccinedelivery and immunogenicity by electroporation in vivo. J Immunol 2000; 164: 4635-40.
15. Chiarella P, Massi E, De Robertis M, et al. Electroporation ofskeletal muscle induces danger signal release and antigenpresentingcell recruitment independently of DNA vaccine administration. Expert Opin Biol Ther 2008; 8: 1645-57.
16. Barouch DH, Santra S, Schmitz JE, et al. Control of viremia andprevention of clinical AIDS in rhesus monkeys by cytokineaugmentedDNA vaccination. Science 2000; 290: 486-92.
17. Barouch DH, McKay PF, Sumida SM, et al. lasmid chemokinesand colony-stimulating factors enhance the immunogenicity ofDNA priming-viral vector boosting human immunodeficiency virustype 1 vaccines. J Virol 2003; 77: 8729-35.
18. Chiarella P, Massi E, De Robertis M, Signori E, Fazio VM. Adjuvantsin vaccines and for immunisation: current trends. Exp Opin Biol Ther 2007; 7: 1551-62.
19. Chiarella P, Massi E, De Robertis M, Fazio VM, Signori E. Strategiesfor effective naked-DNA vaccination against infectious diseases. Recent Pat Antiinfect Drug Discov 2008; 3: 93-101.
20. Dean, DA. Molecule and method for importing DNA into a nucleus. US5827705, 1998.
21. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immuneresponse with improved vaccine adjuvants. Nat Med 2005; 11:S63-S68.
22. Anwer K. 2008 Formulation for DNA delivery via electroporationin vivo From Electroporation protocols: preclinical and clinicalgene medicine. Meth Mol Biol 2005; 423: 77-89.
23. McMahon JM, Signori E, Wells KE, Fazio VM, Wells DJ. Optimisationof electrotransfer of plasmid into skeletal muscle by pretreatmentwith hyaluronidase-increased expression with reducedmuscle damage. Gene Ther 2001; 8: 1264-70.
24. Mathiesen I. Electropermeabilization of skeletal muscle enhancesgene transfer in vivo. Gene Ther 1999; 6: 508-14.
25. Mir LM. Application of electroporation gene therapy: past, currentand future. Methods Mol Biol 2008; 423: 3-17.
26. + T cells. J Immunol 2007; 179: 4741-53.
27. Draghia-Akli R, Khan AS. Antibody production elicited by a DNAvaccine delivered by electroporation. US20090156787, 2009.
28. Luxembourg A, Evams CF, Hannaman D. Electroporation-basedDNA immunisation:translation to the clinic. Exp Opin Biol Ther 2007; 7: 1647-64.
29. Dhama K, Mahendran M, Gupta PK, Rai A. DNA vaccines andtheir applications in veterinary practice: current perspectives. Vet Res Commun 2008; 32: 341-56.
30. Rols MP, Tamzali Y, Teissie J. Electrochemotherapy of horses. Apreliminary clinical report. Bioelectrochemistry 2002; 55: 101-5.
31. Favard C, Dean DS, Rols MP. Electrotransfer as non viral methodof gene delivery. Curr Gene Ther 2007; 7: 67-77.
32. Babiuk S, Baca-Estrada ME, Foldvari M, et al. Needle-free topicalelectroporation improves gene expression from plasmids administeredin porcine skin. Mol Ther 2003; 8: 992-8.
33. Hofmann GA, Rabussay DP, Zhang L. Intradermal delivery ofactive agents by needle-free injection and electroporation. US20077171264, 2007.
34. Liu J, Kjeken R, Mathiesen I, Barouch DH. Recruitment of antigen-presenting cells to the site of inoculation and augmentation ofhuman immunodeficiency virus type 1 DNA vaccine immunogenicityby in vivo electroporation. J Virol 2008; 82: 5643-9.
35. Luckay A, Sidhu MK, Kjeken R, et al. Effect of plasmid DNAvaccine design and in vivo electroporation on the resulting vaccinespecificimmune responses in rhesus macaques. J Virol 2007; 81: 5257-69.
36. Selby M, Walsh R, Pertile T, Goldbeck C, Ulmer J, Liu MA. Electrically-mediated enhancement of DNA vaccine immunity and efficacyin vivo. WOO45823, 2000.
37. Emini EA, Kaslow DC, Bett AJ, Shiver JW, Nicosia A, Lahm A,Luzzago A, Cortese R, Colloca S. Hepatitis C virus vaccine. WO03031588, 2003.
38. Capone S, Zampaglione I, Vitelli A, et al. Modulation of the immuneresponse induced by gene electrotransfer of a hepatitis C virusDNA vaccine in nonhuman primates. J Immunol 2006; 177: 7462-71.
39. Arcuri M, Cappelletti M, Zampaglione I, et al. Synergistic effect ofgene-electro transfer and adjuvant cytokines in increasing the potencyof hepatitis C virus genetic vaccination. J Gene Med 2008; 10: 1048-54.
40. Bodles-Brakhop AM, Heller R, Draghia-Akli, R. Electroporationfor the delivery of DNA-based vaccines and immunotherapeutics:current clinical development. Mol Ther 2009; 17: 585-92.
41. Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress andchallenges. J Immunol 2005; 175: 633-9.
42. Curcio C, Khan AS, Amici A, et al. DNA immunization usingconstant-current electroporation affords long-term protection fromautochthonous mammary carcinomas in cancer-prone transgenicmice. Cancer Gene Ther 2008; 15: 108-14.
43. Pavlenko M, Roos AK, Lundqvist A, et al. Phase I trial of DNAvaccination with a plasmid expressing prostate specific antigen inpatients with hormone-refractory prostate cancer. Br J Cancer 2004; 91: 688-94.
44. Miller AM, Ozenci V, Kiessling R, Pisa P. Immune monitoring in aphase 1 trial of a PSA DNA vaccine in patients with hormonerefractoryprostate cancer. J Immunother 2005; 28: 389-95.
45. Roos AK, King A, Pisa P. DNA vaccination for prostate cancer. Meth Mol Biol 2008; 423: 463-72.
46. Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Prostate stem cell antigen DNA vaccination breaks tolerance toself-antigen and inhibits prostate cancer growth. Mol Ther 2009; 17: 1101-08.
47. Yachnin J. Dose Finding Study of a DNA Vaccine delivered withintradermal electroporation in patients with prostate cancer. NCT00859729; www.cliniclatrials.gov
48. + T cell responses and therapeuticantitumor effect by antigen engineering and electroporation. Vaccine 2009; 27: 5906-12.
49. Yan J, Harris K, Khan AS, et al. Cellular immunity induced by anovel HPV18 DNA vaccine encoding an E6/E7 fusion consensusprotein in mice and rhesus macaques. Vaccine 2008; 26: 5210-5.
50. Chu C, Parker R, Highlands L, Morales J. Phase I of Human Papillomavirus(HPV) DNA Plasmid (VGX-3100) + Electroporation forCIN 2 or 3. NCT00685412; www.cliniclatrials.gov.
51. Merck. A Phase I Study to Evaluate the Safety/Tolerability andImmunogenicity of V-930 in Patients With Cancers Expressing HER-2 and/or CEA. NCT00250419; www.cliniclatrials.gov.
52. Ottensmeier C, Dearnaley D. A Phase I/II Trial of a DNA vaccinegiven to patients with prostate carcinomas with or without electroporationGTAC No089; www.cancerhelp.org.uk/trials
53. Brown PA, Khan AS, Draghia-Akli R. Delivery of DNA into skeletalmuscle in large animals. Meth Mol Biol 2008; 423: 215-24.
54. Escoffre JM, Portet T, Wasungu L, et al. What is (still not) knownof the mechanism by which electroporation mediates gene transferand expression in cells and tissues. Mol Biotechnol 2009; 41: 286-95.
55. Faurie C, Rebersek M, Golzio M, et al. Electro-mediated genetransfer and expression are controlled by the life-time ofDNA/membrane complex formation. J Gene Med 2010; 12: 117-25.
56. Li Z, Zhang H, Fan X, et al. DNA electroporation prime and proteinboost strategy enhances humoural immunity of tubercolosisDNA vaccine in mice and non-human primates. Vaccine 2006; 24: 4565-8.
57. Tjelle TE, Salte R, Mathiesen I, Kjeken RA. Novel electroporationdevice for gene delivery in large animals and humans. Vaccine 2006; 24: 4667-70.
58. Tjelle TE, Rabussay D, Ottensmeier C, Mathiesen I, Kjeken R. Taking electroporation-based delivery of DNA vaccination intohumans: a generic clinical protocol Methods. Mol Biol 2008; 423: 497-507.
59. Mir LM, Gehl J, Sensa G. Standard operating procedures of theelectrochemotherapy: instructions for the use of bleomycin or cysplatinadministered either systemically or locally and electric pulsesdelivered by the Cliniporator TM by means of invasive or noninvasiveelectrodes. Eur J Cancer 2006; 4(Suppl. 11): 14-25.
60. Wells, DJ. Gene therapy progress and prospects: electroporationand other physical methods. Gene Ther 2004; 11: 1363-9.
61. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precisiontools for activating effective immunity against cancer. Nat Rev Cancer 2008; 8: 108-20.